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Abstract
Background: Few data exist that correlate lesion-related risk factors such as conventional cardiovascular risks or
lipoprotein-associated phospholipase A2 (Lp-PLA2) with tissue types within atherosclerotic plaques in patients with
single-vessel and intermediate coronary lesions.
Methods: One hundred and ninety-two patients with single-vessel and intermediate coronary lesions were enrolled
in a cross-sectional study and divided into two groups: stable angina pectoris (SAP) and acute coronary syndrome
(ACS) groups. Data regarding clinical characteristics and Lp-PLA2 mass were collected. Using iMAP-IVUS, lumen
areas were manually traced to determine the minimum lumen area (MLA) at 1-mm intervals in diseased segments. At the
minimum lumen lesion, areas of different types of atherosclerotic tissue [i.e., areas of fibrous plaque tissue (FP), fibro-fatty
tissue (FF), dense calcium (DC) and necrotic core (NC)], vascular external elastic membrane (EEMCSA) and plaque and
media (P&MCSA) were calculated using the built-in iMap algorithm. Plaque burden was computed as P&MCSA
divided by EEMCSA.
Results: In a univariate analysis, glycosylated hemoglobin A1C (GHbA1C), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), hypertension, Lp-PLA2 and a history of taking statins predicted the
degree of FP and NC area, as well as plaque burden, but were not significant predictors of FF or DC area. In a multivariate
analysis, Lp-PLA2 and HbA1c remained independent predictors of plaque burden, FP and NC area. However, the results of
the regression analyses were not identical when the SAP and ACS groups were analyzed separately. Lp-PLA2, diabetes
and NC area were significant predictors of acute coronary lesions, and the predictive value of Lp-PLA2 was confirmed
by the finding of a high area-under-the-curve in a ROC analysis (0.837, 95% CI:0.778-0.895, P = 0.000), as well as by the
reasonable sensitivity and specificity of cut-off values.
Conclusions: GHbA1C and Lp-PLA2 were strong independent predictors of plaque burden and FP and NC area at the
minimum lumen lesion in patients with single-vessel and intermediate coronary lesions. Furthermore, Lp-PLA2 has a
certain predictive value for acute coronary lesions.
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Background
Vulnerable atherosclerotic plaques, which are associated
positively with the presence of more unstable athero-
sclerotic tissue leading to adverse cardiovascular events,
often occur at sites of angiographically intermediate
coronary-artery stenosis. Atherosclerosis and thrombosis
are markedly pathogenic mechanisms that are associated
with the majority of cardiovascular events. Epidemio-
logic data show that the relationship between conven-
tional cardiovascular risk factors and adverse clinical
events in patients with coronary disease is complex [1].
Lp-PLA2 was introduced as an underlying important
pathogenic factor that participates in the generation of
pro-atherogenic metabolites, such as oxidized free fatty
acids and lysophosphatidylcholine [2]. Elevated Lp-PLA2
activity and plasma levels promote an increased risk of
coronary events [3]. Numerous previous reports have
shown that the predictors of culprit or non-culprit lesion-
related major adverse cardiovascular events are associated
with a combination of thin-cap fibroatheroma (TCFA),
plaque burden ≥70%, MLA ≤4.0 mm2, median DC area
≥0.2 mm2, and median NC area ≥0.4 mm2 [4–6]. Whether
established cardiovascular risk factors or Lp-PLA2 can
predict different tissue types within the atherosclerotic
plaque, however, remains unknown. The purpose of this
study was to examine the relationship between conven-
tional cardiovascular risk factors, Lp-PLA2 concentration
and plaque structure parameters as assessed by intravas-
cular ultrasound in patients with either stable angina or
acute coronary syndromes due to intermediate single-
vessel coronary artery lesions.
Methods
Patients
One hundred and ninety-two patients admitted to the
Eighty-first Hospital of PLA (Nanjing, China) were en-
rolled in a cross-sectional study according to the following
criteria: a “target vessel” with angiographically single-vessel
and intermediate coronary lesions (40–70% diameter sten-
osis by visual estimation) subjected to IVUS examination;
the case was considered eligible only if the artery had never
undergone revascularization with previous percutaneous
coronary intervention or coronary-artery bypass grafting.
Patients with multi-vessel coronary artery disease were re-
moved. The enrolled patients were divided into two
groups: SAP (104 cases) and ACS (88 cases with 10.2%
non-STEMI and 89.8% unstable angina) groups. A history
of more than one year with diabetes, hypertension or
smoking (five or more cigarettes per day) and more than
one month of taking aspirin or clopidogrel, statins,
angiotensin-converting enzyme inhibitor or angiotensin re-
ceptor antagonist (ACEI/ARB) were recorded as a distinc-
tion for use as a categorical variable. ACS was defined as
unstable angina or myocardial infarction with or without
ST-segment elevation. Written informed consent was ob-
tained from each patient before initiating the coronary ar-
teriography and IVUS procedure. The protocol was
approved by the Ethics Committee of the Eighty-first
Hospital of PLA Affiliated to Nanjing University of Chinese
Medicine (Nanjing, China). One or more stents was im-
planted in some of the patients according to the diameter
of MLA (≤0.4 mm2) and the length of the lesion-
containing vessel.
Laboratory measurements
All data regarding cardiovascular risk factors and Lp-
PLA2 mass were measured before initiating the coronary
arteriography and IVUS procedure. Fasting venous blood
was collected after admission to the hospital using a vac-
uum blood collection tube coated with EDTA. After
mixing for 10 to 20 min, the plasma samples were sepa-
rated by centrifugation at 1000 to 2000 revolutions per
minute for 20 min at 4 °C. All laboratory examinations
were performed in series from aliquots stored at −80 °C
using commercial kits; the tests included the following:
total cholesterol and triglycerides were measured using
an ARCHITECT c800 analyzer (Abbott Laboratories,
Germany), HDL-C were measured using DOT Diagnos-
tics kits (Czech Republic). LDL was calculated using the
Friedewald equation; i.e., LDL = Total cholesterol −
HDL-C − (triglycerides / 2.22). HbA1c was estimated
based on high-performance liquid chromatography using
a G7 analyzer (TOSOH, Japan).
Lp-PLA2 mass was determined using a commercial
Lp-PLA2-ELISA kit (the PLAC test, supplied by NRM
Inc., Nanjing, China), which is a sandwich enzyme im-
munoassay kit that uses two highly specific monoclonal
antibodies for the measurement of Lp-PLA2 concentra-
tion. A set of calibrators was used to plot a standard
curve of absorbance versus Lp-PLA2 concentration; the
Lp-PLA2 concentration in the test sample was deter-
mined based on this curve, and this ELISA assay had a
detection limit of 100 μg/l. All plasma samples were
tested in duplicate. The intra-assay coefficient of vari-
ation was less than 3.8%, and the inter-assay coefficient
of variation was less than 4.5%.
IVUS disease burden
Quantitative IVUS analysis was performed using the
built-in iMap planimetry function in iMap-IVUS (Boston
Scientific, Natick, MA, USA). Initially, areas of lumen
and vessel inside an external elastic membrane were
manually traced to determine the MLA at every 1-mm
interval in diseased segments. Thereafter, areas of differ-
ent types of atherosclerotic tissue were calculated at the
most severe stegnotic lesion. Cross-sectional areas of
MLA, P&MCSA and EEMCSA were calculated simul-
taneously. P&MCSA = EEMCSA −MLA, and plaque
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burden = P&MCSA /EEMCSA *100%. All iMAP data
were analyzed via standardized criteria at a central core
laboratory.
Statistical analysis
Statistical analysis was performed using SPSS software
(Version 19.0 IBM, Armonk, NY, USA). Categorical vari-
ables are presented as frequencies or percentages and
were compared using chi-square statistics or the Fisher
exact test. Continuous variables were tested for normal
distribution via the non-parametric one-sample Kol-
mogorov–Smirnov test, are presented as the mean ±
SD, and were compared using the independent sam-
ples t-test. Univariate predictors were obtained using
linear regression analysis. Multivariate analysis involved
multiple linear regression analysis with backward or step-
wise selections to determine the risk factors for dependent
variables, and only variables with p ≤0.1 based on univariate
analysis were included. Logistical regression was used to de-
termine the risk factors for ACS, and a ROC curve was
used to describe the diagnostic value. A value of p <0.05
was considered statistically significant.
Results
Baseline data of the two groups
The clinical characteristics are shown in Table 1; based
on these, we can conclude that compared to the SAP
group, the ACS group had higher population proportions
with histories of smoking and diabetes, higher LDL-C
values and Lp-PLA2 masses, and lower HDL-C values. All
patients had a history of taking aspirin or clopidogrel for
at least one month. Lesion-related coronaries and IVUS
disease burden are summarized in Table 2. The values of
EEMCSA, P&MCSA, plaque burden, and areas of FP and
NC were all higher in the ACS group.
Univariate predictors of IVUS disease burden
The univariate analysis predictors of atherosclerotic tis-
sue types and plaque burden are summarized in Table 3
(placed at the end of the document text file because the
table takes up more than one page). Regarding the area
of FP and plaque burden, GHbA1C, total cholesterol, tri-
glycerides, LDL-C, and Lp-PLA2 were found to be pre-
dictors of more severe disease, and HDL-C and statins
were found to be protective factors. Regarding the area
of NC, GHbA1C, total cholesterol, LDL-C, age, hyper-
tension, and Lp-PLA2 were found to be predictors of
more severe disease, and HDL-C was found to be a pro-
tective factor. There were no significant predictors for
areas of tissues of FF and DC.
Multivariate predictors of IVUS disease burden
The multivariate analysis predictors are summarized in
Table 4. In the multivariate analysis, after adjustment for
other risk factors, both Lp-PLA2 and GHbA1C
remained independent predictors of more severe disease
for plaque burden as well as areas of FP and NC. HDL-
C remained a protective factor either for plaque burden
or area of FP in agreement with the univariate regression
models. Suffering from hypertension was independently
associated with increased area of NC.
Univariate and multivariate predictors of IVUS disease
burden in SAP and ACS groups
The results of the regression analyses were not identical
when the SAP and ACS groups were analyzed separately,
whether using a univariate analysis or a multivariate ana-
lysis, as shown in the following Tables 5 and 6. Compared
to the ACS group, in addition to GHbA1C and LDL-C,
Lp-PLA2 and a history of taking statins were found to be
predictors of FP area in the SAP group. A history of taking
ACEI/ARB was a predictor of FP area in the SAP group
but not in the ACS group. Hypertension and Lp-PLA2
were predictors of NC area in both groups. The predictors
of DC area were taking statins in the SAP group and male
gender in the ACS group. The predictors of plaque burden
were HDL-C in the SAP group and LDL-C in the ACS
group, and GHbA1C was a predictor in both groups.
Diabetes and IVUS disease burden
Table 7 summarizes the relationships between IVUS dis-
ease burden and the presence or absence of diabetes. All
IVUS data regarding disease burden were likely to be
more severe in the diabetes group, including P&MCSA,
EEMCSA, MLA, plaque burden, and areas of FP and
NC tissues. However, areas of either FF or DC tissues






Male gender 57(54.81) 59(67.05) 0.085
Hypertension 66(63.46) 54(61.36) 0.765
Diabetes 24(23.08) 48(54.55) 0.000
Smoker 30(28.85) 38(43.18) 0.039
Age, years 65.78 ± 11.51 67.74 ± 12.18 0.254
GHbA1C, mg/dl 6.22 ± 1.00 7.08 ± 1.57 0.000
Lp-PLA2, μg/l 188.24 ± 58.95 271.40 ± 58.53 0.000
Triglycerides, mmol/l 1.66 ± 1.39 1.98 ± 1.48 0.125
Total cholesterol, mmol/l 4.26 ± 1.10 4.58 ± 1.28 0.062
LDL-C, mmol/l 2.68 ± 0.97 3.12 ± 1.14 0.004
HDL-C, mmol/1 1.12 ± 0.27 0.99 ± 0.29 0.003
Medication
Aspirin/ clopidogrel 104(100) 88(100) 1.000
ACEI/ARB 53(50.96) 40(45.45) 0.447
Statins 81(77.88) 62(70.45) 0.239
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Left anterior descending (LAD) 51(49.14) 49(55.68) 0.359
Right coronary artery (RCA) 32(30.77) 24(27.27) 0.595
Left circumflex (LCX) 21(20.19) 15(17.05) 0.578
IVUS data
External elastic membrane (EEMCSA), mm2 11.21 ± 2.44 12.54 ± 2.55 0.000
Minimum lumen area (MLA), mm2 4.30 ± 1.42 4.00 ± 1.30 0.133
Plaque and media (P&MCSA), mm2 6.91 ± 1.86 8.54 ± 2.12 0.000
Plaque burden, % 61.58 ± 9.13 67.77 ± 8.29 0.000
Fibrous plaque tissue (FP), mm2 5.42 ± 1.66 6.46 ± 2.04 0.000
Fibro-fatty tissue (FF), mm2 0.54 ± 0.48 0.53 ± 0.31 0.927
Necrotic core (NC), mm2 0.66 ± 0.32 1.25 ± 0.53 0.000
Dense calcium (DC), mm2 0.29 ± 0.23 0.29 ± 0.21 0.958
Stent implantation 50(48.08) 47(53.41) 0.463



































































































































FP fibrous plaque tissue, FF fibro-fatty tissue, NC necrotic core, DC dense calcium
*p <0.10
**p <0.05
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were not significantly different between patients with or
without diabetes.
Risk factors for the incidence of ACS identified by logistic
regression
Multivariate models including all factors (i.e., conventional
cardiovascular risks, Lp-PLA2, plaque burden and areas of
atherosclerotic tissue types) were analyzed to determine
the risk factors for the incidence of ACS in patients with
single-vessel and intermediate coronary lesions by logistic
regression. Forward selection was chosen to determine
the relevant variables. This model was based only on the
data for the 192 patients enrolled in our study (as summa-
rized in Table 8); based on the results, we concluded that
male gender, LDL-C, Lp-PLA2, diabetes and area of NC
were independent risk factors.
Table 4 Multivariate predictors of IVUS disease burden (n =192)
Variables Selection = Backwarda
βCoeff.(95% CI)




GHbA1C 2.540(1.677 to 3.404) 0.000 2.712(1.863 to 3.561) 0.000
Total cholesterol 1.135(−0.078 to 2.349) 0.066
HDL-C −7.366(−11.688 to −3.043) 0.001 −5.736(−9.718 to −1.755) 0.005
Statins −2.227(−5.296 to 0.843) 0.154 −3.860(−6.401 to −1.319) 0.003
Lp-PLA2 0.020(0.004 to 0.036) 0.015 0.022(0.006 to 0.038) 0.006
FP area
GHbA1C 0.562(0.391 to 0.733) 0.000 0.576(0.408 to 0.744) 0.000
LDL-C 0.521(0.268 to 0.775) 0.000 0.613(0.405 to 0.821) 0.000
HDL-C −0.833(−1.626 to −0.040) 0.040 −0.997(−1.780 to −0.214) 0.013
Statins −0.273(−0.881 to 0.335) 0.376
Lp-PLA2 0.003(0.000 to 0.006) 0.044
NC area
Hypertension 0.163(0.043 to 0.283) 0.008 0.162(0.041 to 0.282) 0.009
GHbA1C 0.042(−0.003 to 0.088) 0.065 0.052(0.007 to 0.096) 0.022
HDL-C −0.147(−0.372 to 0.077) 0.197
Total cholesterol 0.052(−0.001 to −0.105) 0.055
Lp-PLA2 0.004(0.003 to 005) 0.000 0.004(0.003 to 0.005) 0.000
aVariables selected are based on a significance level set at a p value ≤0.1 via univariate analysis
Table 5 Univariate and multivariate predictors of IVUS disease burden in the SAP group
FP area FF area NC area DC area Plaque burden
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
P Value P Value P Value P Value P Value P Value P Value P Value P Value P Value
Male gender 0.858 0.137 0.993 0.186 0.985
Hypertension 0.106 0.042 0.047 0.039 0.916 0.792
Smoker 0.521 0.681 0.885 0.913 0.931
Age 0.447 0.382 0.066 0.919 0.984
GHbA1C 0.000 0.000 0.988 0.043 0.198 0.000 0.001
Triglycerides 0.059 0.891 0.655 0.143 0.061
Total cholesterol 0.000 0.926 0.502 0.439 0.408
LDL-C 0.000 0.054 0.983 0.378 0.555 0.148
HDL-C 0.040 0.293 0.160 0.464 0.002 0.005a
ACEI/ARB 0.729 0.039 0.039a 0.156 0.400 0.487
Statins 0.000 0.002a 0.892 0.975 0.018 0.018 0.218
Lp-PLA2 0.009 0.033 0.163 0.000 0.000 0.067 0.038
aThe β coefficient was found to be negative in the multivariate analysis (with stepwise selection)
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ROC curves for the predictors of the incidence of ACS
Lp-PLA2, GHbA1C (representing diabetes), LDL-C and
NC area were selected as strong risk factors for ACS by
logistic regression as mentioned above. ROC curves were
used to evaluate their diagnostic value and are described
in Fig. 1 (provided as a separate file named “Fig. 1”); we
found that the area under the ROC curve regarding the
Lp-PLA2-predicted incidence of ACS in the 192 patients
was 0.83 (95%CI: 0.778–0.895, P = 0.000); the cut-off value
was 225.5 μg/L, providing a sensitivity of 76.84% and a
specificity of 84.54%. In contrast, GHbA1c and LDL-C
had lower predictive values.
Discussion
Markers of coronary atherosclerotic plaque vulnerability,
such as a thin fibrous cap, increased inflammatory activ-
ity, and a high lipid burden, have been identified in
histological studies. Vulnerable atherosclerotic plaques
that lead to adverse cardiovascular events often occur in
the late stage of coronary artery atherosclerosis and at
sites of angiographically mild or intermediate coronary-
artery stenosis, from which we might argue that angiog-
raphy of the coronary artery does not describe the true
extent of atherosclerosis but only luminal narrowing.
Grayscale IVUS has been used frequently in vivo as a
high-resolution technique for the quantitative assess-
ment of coronary vessel wall anatomy and to provide
more in-depth information than conventional angiog-
raphy but is unable to precisely distinguish between
noncalcific tissue types within the plaque. To solve this
problem, novel modalities of intravascular imaging have
been developed to search for vulnerable plaques by
directly measuring various tissue types within the ath-
erosclerotic plaque. In light of this information, the so-
called “three stars” of IVUS (virtual histology (VH)
IVUS, the integral of backscatter intensities (IB) IVUS,
and iMAP-IVUS) have been introduced. These tech-
niques are based on original radio-frequency IVUS sig-
nals, which are inherently limited for characterizing
tissues, especially in terms of discriminating fatty and fi-
brous tissues [7, 8]; the signals are reprocessed to iden-
tify high-risk atherosclerotic lesions, and each of the
techniques uses a specific mathematical model. The
Table 6 Univariate and multivariate predictors of IVUS disease burden in the ACS group
FP area FF area NC area DC area Plaque burden
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
P Value P Value P Value P Value P Value P Value P Value P Value P Value P Value
Male gender 0.691 0.064 0.789 0.040 0.040a 0.901
Hypertension 0.755 0.621 0.041 0.034 0.142 0.689
Smoker 0.768 0.357 0.383 0.229 0.810
Age 0.509 0.151 0.330 0.181 0.501
GHbA1C 0.000 0.000 0.221 0.640 0.710 0.000 0.000
Triglycerides 0.013 0.518 0.307 0.839 0.054
Total cholesterol 0.015 0.250 0.298 0.561 0.044
LDL-C 0.004 0.003 0.236 0.389 0.375 0.040 0.039
HDL-C 0.268 0.368 0.810 0.608 0.137
ACEI/ARB 0.521 0.911 0.951 0.409 0.684
Statins 0.817 0.352 0.804 0.511 0.207
Lp-PLA2 0.704 0.657 0.000 0.000 0.838 0.743
a The β coefficient was found to be negative in the multivariate analysis (with stepwise selection)







EEMCSA, mm2 12.74 ± 2.52 11.27 ± 2.45 0.000
MLA, mm2 3.88 ± 1.17 4.33 ± 1.45 0.028
P&MCSA, mm2 8.86 ± 2.16 6.94 ± 1.78 0.000
Plaque burden, % 69.11 ± 7.73 61.60 ± 8.99 0.000
FP area, mm2 6.92 ± 1.92 5.28 ± 1.63 0.000
FF area, mm2 0.54 ± 0.37 0.53 ± 0.44 0.890
NC area, mm2 1.09 ± 0.51 0.84 ± 0.51 0.001
DC area, mm2 0.31 ± 0.23 0.28 ± 0.21 0.465
EEMCSA cross-sectional area of external elastic membrane, MLA minimum lumen
area, P&MCSA cross-sectional area of plaque and media
Table 8 Risk factors for the incidence of ACS
Variables OR value 95% CI Wald value P
Male gender 2.832 1.168 to 6.864 5.309 0.021
Diabetes 3.188 1.406 to 7.228 7.703 0.006
Lp-PLA2 1.015 1.008 to 1.022 17.720 0.000
LDL-C 1.687 1.112 to 2.559 6.047 0.014
NC area 9.155 3.102 to 27.015 16.085 0.000
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iMap-IVUS technique used in the present study is based
on a neural network theory and identifies each tissue
using a unique concept of “confidence level” [9]. Unfor-
tunately, when using iMAP-IVUS, the number of refer-
ence points for lipid areas is smaller than that for other
types of atherosclerotic tissue.
Identification of circulating risk or protection markers
that contribute to improving the prediction of adverse
cardiovascular events is, currently, on the frontiers of
cardiology. Two previous studies have suggested that
male gender and diabetes are strong predictors of ath-
erosclerotic plaque burden in patients with coronary ar-
tery disease, although other risks, such as hypertension,
a history of smoking, and prior revascularization or
stroke, remain significant [10, 11]. Compared to previous
reports [10, 11], the patients reported in this study had
relatively mild stenosis (MLA, 4.16 mm2 vs. 1.73 mm2
and 2.26 mm2). In this study, older patients, more
patients with diabetes, and more smokers were included,
as were fewer males; thus, the differences reported may
be due to the differences between the analyzed popula-
tion segments. Notably, both of the two previous studies
lacked data regarding the tissue types within the plaque
due to the inherent limitations of grayscale IVUS. In the
present study, in addition to diabetes, hyperlipidemia
(including higher values of either LDL-C or HDL-C) was
associated with plaque burden and area of FP; this find-
ing is partially consistent with a previous report of a
strong correlation between the serial accumulation of
atheroma and LDL levels [12]. Nevertheless, although
LDL-C and HDL-C were found predictive in our univar-
iate analysis, in terms of their association with the area
of NC, neither was an independent predictor. In light of
these findings, we suggest that lipid levels might be inde-
pendent of their impact on plaque burden and area of
FP tissue; however, we could not rule out the hypothesis
regarding their role in determining plaque vulnerability.
In contrast, male gender and a history of smoking
were less important than expected in this study; this
might have been mainly due to differences in the sample
composition and target points. This study included older
patients, which may lead to a diminished protective ef-
fect of estrogen for females who suffer less coronary
heart disease. However, the data regarding the athero-
sclerotic plaque characteristics investigated in the
present study only contained point variables within the
Fig. 1 Predictive value of Lp-PLA2, GHbA1C, LDL-C and area of NC for ACS. a ROC curves for the four variables. b Area under the curve
(AUC) and cut-off values
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most diseased segment, except for the three-dimensional
variables, such as average plaque area and percent
plaque volume, which may also have affected the risks
factor analysis, positively; this was also considered a po-
tential data limitation.
All IVUS data regarding disease burden were likely to
have been more severe in diabetes group in this study.
We therefore hypothesized that the diabetic state is re-
sponsible for the development of atherosclerotic plaque
based on relatively convincing evidence, and this evi-
dence suggested a strong correlation between enhanced
atheroma burden and increased event rates of ACS.
Various abnormalities of hematologic and vascular func-
tion in patients with diabetes might result in endothelial
dysfunction and subsequently enhanced platelet activity
[13]. However, the detailed pathogenic mechanisms cor-
relating plaque tissue types with diabetes have not been
extensively investigated.
Currently, LP-PLA2 has been introduced as a new
marker of atherosclerotic plaque destabilization, which
plays a key role in the generation of pro-atherogenic me-
tabolites and the metabolism of pro-inflammatory phos-
pholipids. In the present study, Lp-PLA2 independently
showed significant correlations with the IVUS data re-
garding disease burden, especially with the area of NC,
and exhibited a high predictive value for acute coronary
lesions; this result might agree with the results of a trial
in dyslipidemic and diabetic pigs: darapladib (which ex-
hibits a pharmacological inhibition of Lp-PLA2) reduced
Lp-PLA2 levels in coronary atherosclerotic plaques and
decreased the necrotic core in the plaques [14]. How-
ever, the results of two randomized trials (STABIL-
ITY[15] and the SOLID-TIMI 52 [16], which were
conducted to test whether darapladib reduces cardiovas-
cular events in stable and unstable coronary heart dis-
ease) did not demonstrate any beneficial effect on any of
the primary endpoints (cardiovascular death, stroke, myo-
cardial infarction, or urgent coronary artery revasculariza-
tion). These disappointing results might seem to cast
doubt on the pathogenic role of Lp-PLA2 in atheroscler-
otic plaque destabilization. However, taking into consider-
ation the well-founded plethora of data demonstrating
that Lp-PLA2 predicts cardiovascular events, one could
argue that Lp-PLA2 does not play a causative role in these
events but only serves as a prognostic marker.
Statins, cholesterol-lowering drugs, were found to re-
duce plasma Lp-PLA2 activity because most plasma Lp-
PLA2 is linked to LDL-C [17, 18]. Treatment with statin
brings demonstrable benefits in terms of lowering mortal-
ity and cardiovascular event rates, and this might be ex-
plained by the reduction of Lp-PLA2, which was
demonstrated to be predictive, or even more predictive,
than a decrease in LDL cholesterol [17]. In this study, a
history of taking statins was found to be a predictor of FP
area only in the SAP group (not in the ACS group) after
adjusting for other factors, including LDL-C and Lp-
PLA2. However, none of these studies was able to deter-
mine whether the decrease of Lp-PLA2 was associated
with a reduction of the associated enzyme activity in the
atherosclerotic plaque.
Several potential limitations of our study should be
noted. First, this study was based on a relatively small sam-
ple. Second, based on this single-center and cross-sectional
study, we could not investigate more deeply regarding the
correlations between conventional cardiovascular risk fac-
tors, Lp-PLA2 and cardiovascular events due to the lack of
follow-up data.
Conclusions
The data obtained in the present study indicate that
GHbA1C and Lp-PLA2 are strong independent predic-
tors of plaque burden and areas of FP and NC in the
most severe stegnotic lesions in patients with single-
vessel and intermediate coronary lesions. LDL-C and
HDL-C were found to be independent predictors of
plaque burden and the area of FP but not for the area of
NC. However, hypertension was independently associ-
ated with an increased area of NC. No significant predic-
tors were found for areas of tissues of FF and DC mainly
due to limitations involving the discrimination of the
two tissues when using iMAP-IVUS. Lp-PLA2 has a cer-
tain predictive value for the incidence of ACS in patients
with single-vessel and intermediate coronary lesions. Fu-
ture studies are warranted to evaluate whether decreas-
ing the mass of Lp-PLA2 using an effective antagonist
will abate the areas of plaque tissue, especially NC tissue,
thus reducing the incidence of cardiovascular events.
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